Compare QGEN to:
Real-Time: 21.64 -0.18 (-0.82%) 10:20am ET
| Last Trade: | 21.585 |
|---|---|
| Trade Time: | 10:06am ET |
| Change: | |
| Prev Close: | 21.82 |
| Open: | 21.49 |
| Bid: | 21.57 x 200 |
| Ask: | 21.58 x 700 |
| 1y Target Est: | 24.28 |
| Day's Range: | 21.49 - 21.69 |
|---|---|
| 52wk Range: | 14.32 - 23.58 |
| Volume: | 150,803 |
| Avg Vol (3m): | 1,222,510 |
| Market Cap: | 4.99B |
| P/E (ttm): | 37.41 |
| EPS (ttm): | 0.577 |
| Div & Yield: | N/A (N/A) |
| Fri, Nov 20 | Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research AnalystWall Street Transcript |
| Tue, Nov 10 | Q3 2009 Qiagen N.V. Earnings Release - Time Not SuppliedCCBN |
| Mon, Nov 9 | QIAGEN to Acquire SABiosciencesMarketwire |
| Mon, Nov 9 | UPDATE - Qiagen beats estimates, tweaks outlook on test salesat Reuters |
| Mon, Nov 9 | QIAGEN Reports Strong Third Quarter 2009 ResultsGlobeNewswire |
| Mon, Nov 9 | Healthcare Bill Will Be Law By New Year Says Morningstar StrategistWall Street Transcript |
| Sat, Nov 7 | [$$] Stocks Jump Despite Rising Unemploymentat Barrons.com |
| Thu, Nov 5 | QIAGEN and British Veterinary Laboratories Agency Expand Partnership in Veterinary TestingBusiness Wire |
| Tue, Nov 3 | Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2009 Financial Results Call Set for November 10PR Newswire |
| Tue, Oct 20 | Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan AnalystWall Street Transcript |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.